Unknown

Dataset Information

0

The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.

ABSTRACT: A number of specific chromosomal abnormalities define the subgroups of multiple myeloma. In a meta-analysis of two genome-wide association studies of multiple myeloma including a total of 1,661 affected individuals, we investigated risk for developing a specific tumor karyotype. The t(11;14)(q13;q32) translocation in which CCND1 is placed under the control of the immunoglobulin heavy chain enhancer was strongly associated with the CCND1 c.870G>A polymorphism (P = 7.96 × 10(-11)). These results provide a model in which a constitutive genetic factor is associated with risk of a specific chromosomal translocation.

SUBMITTER: Weinhold N 

PROVIDER: S-EPMC5056630 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

A number of specific chromosomal abnormalities define the subgroups of multiple myeloma. In a meta-analysis of two genome-wide association studies of multiple myeloma including a total of 1,661 affected individuals, we investigated risk for developing a specific tumor karyotype. The t(11;14)(q13;q32) translocation in which CCND1 is placed under the control of the immunoglobulin heavy chain enhancer was strongly associated with the CCND1 c.870G>A polymorphism (P = 7.96 × 10(-11)). These results p  ...[more]

Similar Datasets

Genomics Genomic imbalances in BCL1/JH t(11;14)(q13;q32) positive multiple myeloma
2012-12-31 | GSE33757 | GEO
Transcriptomics Genomic imbalances in BCL1/JH t(11;14)(q13;q32) positive multiple myeloma
2012-12-31 | E-GEOD-33757 | biostudies-arrayexpress
Unknown Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study.
| S-EPMC3475941 | biostudies-literature
Unknown <i>MYEOV</i> gene overexpression in primary plasma cell leukemia with t(11;14)(q13;q32).
| S-EPMC4950221 | biostudies-literature
Unknown HLA polymorphism and risk of multiple myeloma.
| S-EPMC5134914 | biostudies-literature
Unknown Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma.
| S-EPMC1609182 | biostudies-literature
Unknown What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?
| S-EPMC7649769 | biostudies-literature
Unknown Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14).
| S-EPMC9581939 | biostudies-literature
Unknown Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14).
| S-EPMC7049357 | biostudies-literature
Unknown Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma.
| S-EPMC8729045 | biostudies-literature